(Q37579455)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Dabigatran etexilate: future directions in anticoagulant treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Paul A Reilly

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

13 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Applied Thrombosis-Hemostasis

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

15 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

32S-41S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

Why do patients with atrial fibrillation not receive warfarin?

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Ximelagatran: direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Stroke severity in atrial fibrillation. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Letter by Secchiero and Zauli regarding article, "Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609344199

21 January 2018

Identifiers

DOI

10.1177/1076029609344199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19679590%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference